Skip to main navigation Skip to search Skip to main content

Production and regulatory issues for theranostics

  • Francesco Giammarile
  • , Diana Paez
  • , Richard Zimmermann
  • , Cathy S. Cutler
  • , Amirreza Jalilian
  • , Aruna Korde
  • , Peter Knoll
  • , Nayyereh Ayati
  • , Jason S. Lewis
  • , Suzanne E. Lapi
  • , Roberto C. Delgado Bolton
  • , Jolanta Kunikowska
  • , Enrique Estrada Lobato
  • , Jean-Luc Urbain
  • , Ola Holmberg
  • , May Abdel-Wahab
  • , Andrew M. Scott

Research output: Contribution to journal › Review Article › Other › peer-review

Abstract

Theranostics has become a major area of innovation and progress in cancer care over the last decade. In view of the introduction of approved therapeutics in neuroendocrine tumours and prostate cancer in the last 10 years, the ability to provide access to these treatments has emerged as a key factor in ensuring global benefits from this cancer therapy approach. In this Series paper we explore the issues that affect access to and availability of theranostic radiopharmaceuticals, including supply and regulatory issues that might affect the availability of theranostic treatments for patients with cancer.

Original languageEnglish
Pages (from-to)e260-e269
Number of pages10
JournalThe Lancet Oncology
Volume25
Issue number6
DOIs
Publication statusPublished - Jun 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being
  2. SDG 9 - Industry, Innovation, and Infrastructure
    SDG 9 Industry, Innovation, and Infrastructure

Cite this